Skip to main content
    C

    Cytosorbents Crp (CTSO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.85
    -0.02 (-0.41%)

    Market Cap: $15.35M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cytosorbents Crp (CTSO) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Cytosorbents Crp reported EPS of -$0.58, above the -$0.90 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    40%(16/40)
    Avg Surprise
    -18.98%
    Streak
    1 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.71
    Range-$0.78 - -$0.63
    5 analysts
    Revenue Consensus
    $10.67M
    Range$9.72M - $11.55M
    4 analysts

    Next Report

    CTSO's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    CTSO Earnings Call

    The latest CTSO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CTSO beat 16, missed 20 and matched 4. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 162.66% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.58-$0.90-$1.00 - -$0.80+35.56%BeatN/A20 up, 2 downNov 12, 2026N/A
    Jun 30, 2026-$0.07-$0.05-$0.05 - -$0.04-40.00%MissN/A31 up, 0 downAug 6, 2026$9.63M
    Mar 31, 2026-$0.08-$0.05-$0.06 - -$0.05-60.00%MissN/A20 up, 0 downMay 13, 2026$8.86M
    Dec 31, 2025-$0.09-$0.04-$0.06 - -$0.04-104.08%MissN/A31 up, 1 downMar 25, 2026$9.23M
    Sep 30, 2025-$0.05-$0.05-$0.06 - -$0.030.00%In lineN/A30 up, 1 downNov 13, 2025$9.48M
    Jun 30, 2025-$0.05-$0.07N/A+28.57%BeatN/AN/A0 up, 0 downAug 7, 2025$9.62M
    Mar 31, 2025-$0.02-$0.07N/A+71.43%BeatN/AN/A0 up, 0 downMay 14, 2025$8.73M
    Dec 31, 2024-$0.14-$0.05N/A-162.66%MissN/AN/A0 up, 0 downMar 31, 2025$9.15M
    Sep 30, 2024-$0.08-$0.06-$0.08 - -$0.05-33.33%MissN/A30 up, 0 downNov 7, 2024$8.61M
    Jun 30, 2024-$0.08-$0.10-$0.11 - -$0.09+20.00%BeatN/A40 up, 0 downAug 13, 2024$8.84M
    Mar 31, 2024-$0.12-$0.12-$0.15 - -$0.100.00%In lineN/A30 up, 0 downMay 9, 2024$8.99M
    Dec 31, 2023-$0.13-$0.14-$0.22 - -$0.08+7.14%BeatN/A40 up, 0 downMar 14, 2024$3.40M
    Sep 30, 2023-$0.21-$0.12-$0.14 - -$0.10-75.00%MissN/A60 up, 0 downNov 9, 2023$8.81M
    Jun 30, 2023-$0.14-$0.14-$0.16 - -$0.040.00%In lineN/A40 up, 0 downAug 1, 2023$9.42M
    Mar 31, 2023-$0.17-$0.13-$0.16 - -$0.08-30.77%MissN/A30 up, 0 downMay 2, 2023$9.45M
    Dec 31, 2022-$0.01-$0.01N/A-33.33%MissN/A50 up, 0 downMar 9, 2023$9.39M
    Sep 30, 2022-$0.28-$0.16-$0.19 - -$0.13-75.00%MissN/A40 up, 0 downNov 3, 2022$8.11M
    Jun 30, 2022-$0.25-$0.12-$0.18 - -$0.07-108.33%MissN/A40 up, 0 downAug 2, 2022$8.50M
    Mar 31, 2022-$0.21-$0.14-$0.17 - -$0.07-50.00%MissN/A40 up, 0 downMay 3, 2022$8.69M
    Dec 31, 2021-$0.21-$0.13-$0.18 - -$0.07-61.54%MissN/A50 up, 0 downMar 8, 2022$10.78M
    Sep 30, 2021-$0.15-$0.12-$0.14 - -$0.06-25.00%MissN/A50 up, 0 downNov 4, 2021$9.76M
    Jun 30, 2021-$0.11-$0.05-$0.06 - $0.03-120.00%MissN/A7N/AAug 3, 2021$12.02M
    Mar 31, 2021-$0.10-$0.05-$0.09 - $0.06-100.00%MissN/A6N/AMay 4, 2021$10.60M
    Dec 31, 2020-$0.01-$0.04-$0.07 - $0.01+75.00%BeatN/A8N/AMar 9, 2021$11.96M
    Sep 30, 2020-$0.02-$0.09-$0.14 - -$0.05+77.78%BeatN/A8N/ANov 4, 2020$10.55M
    Jun 30, 2020-$0.08-$0.09-$0.11 - -$0.05+11.11%BeatN/A6N/AAug 4, 2020$9.79M
    Mar 31, 2020-$0.10-$0.15-$0.21 - -$0.09+33.33%BeatN/A4N/AMay 5, 2020$8.71M
    Dec 31, 2019-$0.12-$0.16-$0.23 - -$0.10+25.00%BeatN/A5N/AMar 5, 2020$7.43M
    Sep 30, 2019-$0.21-$0.14-$0.18 - -$0.11-50.00%MissN/A5N/ANov 5, 2019$6.10M
    Jun 30, 2019-$0.11-$0.14-$0.17 - -$0.10+21.43%BeatN/A5N/AAug 6, 2019$6.23M
    Mar 31, 2019-$0.15-$0.18-$0.22 - -$0.15+16.67%BeatN/A3N/AMay 7, 2019$5.19M
    Dec 31, 2018-$0.17-$0.13-$0.15 - -$0.12-30.77%MissN/A5N/AMar 7, 2019$6.08M
    Sep 30, 2018-$0.10-$0.14-$0.16 - -$0.12+28.57%BeatN/A4N/ANov 6, 2018$5.74M
    Jun 30, 2018-$0.19-$0.13-$0.15 - -$0.05-46.15%MissN/A4N/AAug 2, 2018$5.76M
    Mar 31, 2018-$0.10-$0.13-$0.16 - -$0.03+23.08%BeatN/A4N/AMay 8, 2018$4.92M
    Dec 31, 2017-$0.11-$0.09-$0.14 - -$0.06-22.22%MissN/A4N/AMar 8, 2018$4.65M
    Sep 30, 2017-$0.07-$0.07-$0.11 - -$0.050.00%In lineN/A5N/ANov 9, 2017$3.82M
    Jun 30, 2017-$0.04-$0.06-$0.07 - -$0.05+33.33%BeatN/A5N/AAug 7, 2017$3.57M
    Mar 31, 2017-$0.05-$0.10N/A+50.00%BeatN/AN/AN/AMay 8, 2017$3.11M
    Dec 31, 2016-$0.17-$0.09N/A-88.89%MissN/AN/AN/AMar 3, 2017$3.08M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.21, after -$0.42 the year before. It was -$0.48 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.21N/A
    Dec 31, 2024-$0.42N/A
    Dec 31, 2023-$0.65N/A
    Dec 31, 2022-$0.75N/A
    Dec 31, 2021-$0.57N/A
    Dec 31, 2020-$0.21N/A
    Dec 31, 2019-$0.59N/A
    Dec 31, 2018-$0.56N/A
    Dec 31, 2017-$0.27N/A
    Dec 31, 2016-$0.48N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,9555
    2026Q2Jun 30, 20268,1666
    2026Q1Mar 31, 20265,7197
    2025Q4Dec 31, 20253,7897
    2025Q3Sep 30, 20252,8675
    2025Q2Jun 30, 20253,5056
    2025Q1Mar 31, 20255,3148
    2024Q3Sep 30, 20245,1236

    2026Q3 Earnings Call

    Opening remarks

    Peter Mariani CFO Thank you, John, and good afternoon, everyone. Joining me on today's call is Dr. Phillip Chan, our Chief Executive Officer. As we get started this evening, I want to remind everyone that our press release has been filed and is available with the SEC, but given the several delays that many of us have experienced today, apparently there's a delay with the wire service, so hopefully we'll see that cross the wire here very soon. On today's call, we will review our third quarter 2026 operating and financial results, including the key milestone highlighted in today's earnings release, the achievement of our first value driver, operating cash flow breakeven. We will then provide an update on our remaining value drivers, including our regulatory progress with DrugSorb-ATR, followed by a question-and-answer session. Before we begin, I'd like to remind everyone that statements made during this call that are not historical facts are forward-looking statements, and the company claims protection under the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements about our plans, objectives, future targets and outlook, our ability to sustain operating cash flow breakeven, the outcome of our regulatory submissions, our ability to maintain compliance with NASDAQ continued listing requirements, and our ability to finance the company, including the extension, refinancing, or repayment of our existing debt. Actual results may differ materially from those expressed or implied in these statements. For the discussion of risks and uncertainties that could cause such differences, please refer to the risk factors in our annual report on Form 10-K filed with the SEC on March 30, 2026, as updated by our quarterly reports on Form 10-Q, including the 10-Q we expect to file by Monday, November 16th. We undertake no obligation to update any forward-looking statements, except as required by law. During this call, we will also refer to certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net loss, and adjusted net loss per share. Reconciliations of these measures to the most directly comparable GAAP measures are included in our earnings press release, which is available on the investor relations section of our website. Also note that our share and per-share amounts reflect the 1-for-20 reverse stock split effected on September 8th, 2026. With that, I'll turn the call over to Phil. Phil?

    Phillip Chan CEO Great. Thank you very much, Pete. Well, thanks, Pete, and good afternoon, everyone. I appreciate you joining us. This was an important quarter for Cytosorbents, not just because of the financial results, but because of what they tell us about the business that we're building.

    Frequently Asked Questions About CTSO

    Did CTSO beat earnings estimates last quarter?

    Yes. Cytosorbents Crp reported EPS of -$0.58 for the quarter ended Sep 30, 2026, above the -$0.90 estimate, a 35.56% surprise.

    What EPS do analysts expect from CTSO next quarter?

    The consensus EPS estimate for Cytosorbents Crp for the quarter ending Dec 31, 2026 is -$0.71 from 5 analysts, with estimates from -$0.78 to -$0.63.

    How often does CTSO beat earnings estimates?

    Cytosorbents Crp beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -28.90%.